Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2020 | 1 |
2023 | 1 |
2024 | 1 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
Geographic variation in sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia.
Diabetes Obes Metab. 2024 Apr 15. doi: 10.1111/dom.15597. Online ahead of print.
Diabetes Obes Metab. 2024.
PMID: 38618983
Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in Australia in the era of increased evidence of their cardiovascular benefits (2014-2022).
Lin J, Pearson SA, Greenfield JR, Park KH, Havard A, Brieger D, Day RO, Falster MO, de Oliveira Costa J.
Lin J, et al.
Eur J Clin Pharmacol. 2023 Sep;79(9):1239-1248. doi: 10.1007/s00228-023-03539-8. Epub 2023 Jul 14.
Eur J Clin Pharmacol. 2023.
PMID: 37449993
Free PMC article.
Item in Clipboard
Ocular Chlamydia trachomatis infection, anti-Pgp3 antibodies and conjunctival scarring in Vanuatu and Tarawa, Kiribati before antibiotic treatment for trachoma.
Butcher R, Handley B, Garae M, Taoaba R, Pickering H, Bong A, Sokana O, Burton MJ, Sepúlveda N, Cama A, Mesurier RL, Solomon AW, Mabey D, Taleo F, Tekeraoi R, Roberts CH.
Butcher R, et al.
J Infect. 2020 Apr;80(4):454-461. doi: 10.1016/j.jinf.2020.01.015. Epub 2020 Feb 1.
J Infect. 2020.
PMID: 32017971
Free PMC article.
Item in Clipboard
Cite
Cite